These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 17973263)

  • 21. [HER-2 overexpression and gene amplification of advanced breast cancers determined by fluorescence in situ hybridization in fine needle aspiration specimens].
    Zhang Z; Zhao L; Guo H; Guo L; Ling Y; Xu X; Zhao H; Pan Q
    Zhonghua Zhong Liu Za Zhi; 2014 Mar; 36(3):183-7. PubMed ID: 24785277
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison Between HER2, Estrogen Receptors and Progesterone Receptors in Primary Breast Carcinomas and Matched Lymph Node Metastases.
    Desouki MM; Atta IS; Wolff DJ; Self SE
    Turk Patoloji Derg; 2016; 32(3):178-85. PubMed ID: 27562392
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Concordance of HER2 status in primary tumour and lymph node metastases in patients with esophageal carcinoma.
    König AM; Reeh M; Dancau AM; Rathjens M; Gros S; Uzunoglu FG; Bockhorn M; Simon R; Sauter G; Marx A; Izbicki JR
    Anticancer Res; 2013 Nov; 33(11):4975-82. PubMed ID: 24222138
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients.
    Kuo SJ; Wang BB; Chang CS; Chen TH; Yeh KT; Lee DJ; Yin PL; Chen M
    Taiwan J Obstet Gynecol; 2007 Jun; 46(2):146-51. PubMed ID: 17638622
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan.
    Sharif MA; Mamoon N; Mushtaq S; Khadim MT
    J Coll Physicians Surg Pak; 2009 Feb; 19(2):99-103. PubMed ID: 19208313
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potential for HER-2/neu molecular targeted therapy for invasive bladder carcinoma: comparative study of immunohistochemistry and fluorescent in situ hybridization.
    Matsubara H; Yamada Y; Naruse K; Nakamura K; Aoki S; Taki T; Tobiume M; Zennami K; Katsuda R; Honda N
    Oncol Rep; 2008 Jan; 19(1):57-63. PubMed ID: 18097576
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Organotropism and prognostic marker discordance in distant metastases of breast carcinoma: fact or fiction? A clinicopathologic analysis.
    St Romain P; Madan R; Tawfik OW; Damjanov I; Fan F
    Hum Pathol; 2012 Mar; 43(3):398-404. PubMed ID: 21840040
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Concordance Between FISH Analysis of Her-2/Neu Gene in Breast Duct Carcinoma and Corresponding Axillary Nodal Metastases: Egyptian National Cancer Institute Experience.
    Badawy OM; Hassan H; ELBakey HA; Mosaad M
    Appl Immunohistochem Mol Morphol; 2019 Apr; 27(4):295-300. PubMed ID: 29750667
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Longitudinal evaluation of cytogenetic aberrations in prostatic cancer: tumours that recur in time display an intermediate genetic status between non-persistent and metastatic tumours.
    Alers JC; Krijtenburg PJ; Hop WC; Bolle WA; Schröder FH; van der Kwast TH; Bosman FT; van Dekken H
    J Pathol; 1998 Jul; 185(3):273-83. PubMed ID: 9771481
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The expression of p53, bcl-2, bax, fas and fasL in the primary tumour and lymph node metastases of breast cancer.
    Sjöström-Mattson J; Von Boguslawski K; Bengtsson NO; Mjaaland I; Salmenkivi K; Blomqvist C
    Acta Oncol; 2009; 48(8):1137-43. PubMed ID: 19863221
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Microinvasive breast cancer: ER, PR, and HER-2/neu status and clinical outcomes after breast-conserving therapy or mastectomy.
    Margalit DN; Sreedhara M; Chen YH; Catalano PJ; Nguyen PL; Golshan M; Overmoyer BA; Harris JR; Brock JE
    Ann Surg Oncol; 2013 Mar; 20(3):811-8. PubMed ID: 22956068
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A retrospective study of metachronous and synchronous ipsilateral supraclavicular lymph node metastases in breast cancer patients.
    Fan Y; Xu B; Liao Y; Yao S; Sun Y
    Breast; 2010 Oct; 19(5):365-9. PubMed ID: 20399657
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Heterogeneity of ERBB2 in gastric carcinomas: a study of tissue microarray and matched primary and metastatic carcinomas.
    Cho EY; Park K; Do I; Cho J; Kim J; Lee J; Kim S; Kim KM; Sohn TS; Kang WK; Kim S
    Mod Pathol; 2013 May; 26(5):677-84. PubMed ID: 23238628
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of primary breast cancer and paired metastases: biomarkers discordance influence on outcome and therapy.
    Ongaro E; Gerratana L; Cinausero M; Pelizzari G; Poletto E; Giangreco M; Andreetta C; Pizzolitto S; Di Loreto C; Minisini AM; Mansutti M; Russo S; Fasola G; Puglisi F
    Future Oncol; 2018 Apr; 14(9):849-859. PubMed ID: 29527957
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours.
    Fleischmann A; Rotzer D; Seiler R; Studer UE; Thalmann GN
    Eur Urol; 2011 Aug; 60(2):350-7. PubMed ID: 21640482
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Her-2 amplification and p185 expression in invasive breast cancer cells in women].
    Titi S
    Ann Acad Med Stetin; 2006; 52(2):5-12. PubMed ID: 17633393
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hormone receptors and HER2 expression in primary breast carcinoma and corresponding lymph node metastasis: do we need both?
    Raica M; Cîmpean AM; Ceausu RA; Fulga V; Nica C; Rudico L; Saptefrati L
    Anticancer Res; 2014 Mar; 34(3):1435-40. PubMed ID: 24596391
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Conversion of hormone and HER-2 receptor in metachronous neck metastases from breast carcinoma.
    Nauroth A; Kalder M; Rössler M; Wichmann G; Dietz A; Wiegand S
    J Cancer Res Clin Oncol; 2017 Sep; 143(9):1811-1814. PubMed ID: 28429100
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and paired metastases: clinical impact.
    Ibrahim T; Farolfi A; Scarpi E; Mercatali L; Medri L; Ricci M; Nanni O; Serra L; Amadori D
    Oncology; 2013; 84(3):150-7. PubMed ID: 23257904
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysis.
    Houssami N; Macaskill P; Balleine RL; Bilous M; Pegram MD
    Breast Cancer Res Treat; 2011 Oct; 129(3):659-74. PubMed ID: 21698410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.